Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Clinical Pharmacokinetics|July 28, 2023
CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy AdultsAmin Muhareb, Antje Blank, Andreas D Meid, et al.
British Journal of Clinical Pharmacology|September 8, 2018
Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoidedAndrea Huppertz, Lars Werntz, Andreas D Meid, et al.
Clinical Pharmacokinetics|February 23, 2024
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy VolunteersBrit S Rohr, Evelyn Krohmer, Kathrin I Foerster, et al.
Cancers|July 18, 2020
Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IM-MS/MS AssayMargaux Fresnais, André Roth, Kathrin I Foerster, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 8, 2019
An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasmaMax Sauter, Philipp Uhl, Kathrin I Foerster, et al.
Analytical Chemistry|July 10, 2018
Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based AssayKathrin I Foerster, Andrea Huppertz, Andreas D Meid, et al.
Clinical Pharmacology and Therapeutics|June 2, 2019
Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy VolunteersAndrea Huppertz, Christian Ott, Thomas Bruckner, et al.
British Journal of Clinical Pharmacology|October 10, 2023
Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case reportRémi Longuespée, Julia Kunz, Margaux Fresnais, et al.
Cardiovascular Drugs and Therapy|March 4, 2023
Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail ApproachAlexander Lenard, Simon A Hermann, Felicitas Stoll, et al.
Frontiers in Pharmacology|April 28, 2025
Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteersAlexander Lenard, Simon A Hermann, Felicitas Stoll, et al.
Pageof 4